Asahi Kasei

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

4 Stories Indexed

Last Updated: Just Now

Verified Entity Intelligence

Clean Energy & Climate Transition 04 Oct 2026, 02:18 PM IST

Giant Australian Stick Insect Mystery Solved After Decades of Scientific Misidentification

Scientists have resolved a long-running taxonomic puzzle involving a giant Australian stick insect that had been misclassified for decades, revealing that what was thought to be one species is in fact two distinct species. The finding sharpens understanding of Australia’s insect biodiversity and underscores how modern taxonomy can still uncover hidden species in well-studied ecosystems.

By RDU Global Wire5 min read

Global Markets & Equities04 Oct 2026, 07:18 AM IST

SpaceX’s Latest Starship Flight Wins Analyst Approval as Program Advances Toward Reusable Heavy Lift

SpaceX’s latest Starship test flight drew a positive response from analysts after the vehicle completed key mission objectives and offered fresh data on heat shield performance, splashdown recovery and overall system maturity. The result reinforces confidence that the world’s most powerful rocket is moving closer to operational relevance, even as major technical and regulatory hurdles remain.

6 min readRead →

Global Markets & Equities11 Oct 2026, 12:38 PM IST

US FDA Approves Asahi Kasei’s HOVILPRI for Persistent Herpes Infections

The US Food and Drug Administration has approved Asahi Kasei’s HOVILPRI, a pritelivir tablet for immunocompromised adults with mucocutaneous herpes simplex virus lesions that are refractory to standard antiviral treatment, with or without resistance. The decision marks a notable advance in a niche but clinically urgent market, offering an oral option where treatment has often been limited and difficult to manage. The approval also gives Asahi Kasei a meaningful regulatory win in the United States and could reshape care pathways for a small but high-need patient population.

5 min readRead →

Global Markets & Equities11 Oct 2026, 04:47 AM IST

US FDA Clears Asahi Kasei’s Hovilpri for Persistent Herpes Infections

The U.S. Food and Drug Administration has approved Asahi Kasei’s Hovilpri, a treatment for refractory herpes simplex virus lesions in immunocompromised adults, marking a notable regulatory win for the Japanese industrial group’s healthcare portfolio. The decision could expand access to an oral option for patients with persistent or resistant infections, a category that has often required more burdensome intravenous care.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Asahi Kasei:

U.S. Food and Drug Administration(2)Washington, D.C.(1)United States(1)SpaceX(1)ScienceDaily(1)Pacific Ocean(1)